WallStSmart
ADCT

ADC Therapeutics SA

NYSE: ADCT · HEALTHCARE · BIOTECHNOLOGY

$3.78
+0.27% today

Updated 2026-04-29

Market cap
$480.78M
P/E ratio
P/S ratio
5.91x
EPS (TTM)
$-1.12
Dividend yield
52W range
$1 – $5
Volume
0.9M

ADC Therapeutics SA (ADCT) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item201720182019202020212022202320242025
Revenue$1.80M$1.14M$2.34M$0.00$33.92M$209.91M$69.56M$70.84M$81.36M
Revenue growth (YoY)-36.8%+105.3%-100.0%+518.9%-66.9%+1.8%+14.9%
Cost of revenue$85.53M$118.09M$107.54M$141.82M$1.39M$3.30M$2.53M$5.95M$7.67M
Gross profit$-83.73M$-116.95M$2.34M$-141.82M$32.52M$206.61M$67.03M$64.89M$73.68M
Gross margin-4643.8%-10258.4%100.0%95.9%98.4%96.4%91.6%90.6%
R&D$85.53M$118.31M$107.54M$142.03M$158.00M$186.46M$127.13M$109.63M$104.00M
SG&A$7.81M$8.60M$14.20M$55.13M$71.46M$107.74M$72.88M$64.47M$36.56M
Operating income$-91.67M$-125.94M$-119.40M$-219.26M$-261.72M$-123.34M$-165.99M$-130.65M$-108.38M
Operating margin-5084.3%-11047.5%-5102.5%-771.6%-58.8%-238.6%-184.4%-133.2%
EBITDA$-91.33M$-122.36M$-114.10M$-218.23M$-230.53M$-107.70M$-145.83M$-102.65M$-106.50M
EBITDA margin-5065.4%-10733.2%-4876.1%-679.7%-51.3%-209.6%-144.9%-130.9%
EBIT$-91.67M$-122.87M$-115.75M$-219.05M$-233.16M$-110.09M$-149.09M$-105.92M$-108.38M
Interest expense$2.68M$3.28M$156000.00$4.93M$18.34M$36.73M$46.33M$50.21M$51.63M
Income tax$48000.00$224000.00$582000.00$327000.00$-21.48M$227000.00$39.11M$166000.00
Effective tax rate-0.1%-0.2%-0.5%-0.1%8.5%-0.1%-19.5%-0.1%0.0%
Net income$-89.86M$-123.10M$-116.48M$-246.29M$-230.03M$-157.13M$-240.05M$-157.85M$-142.62M
Net income growth (YoY)-37.0%+5.4%-111.4%+6.6%+31.7%-52.8%+34.2%+9.6%
Profit margin-4984.0%-10797.9%-4977.9%-678.2%-74.9%-345.1%-222.8%-175.3%